International Journal of Infertility & Fetal Medicine

Register      Login

VOLUME 7 , ISSUE 3 ( September-December, 2016 ) > List of Articles

RESEARCH ARTICLE

Comparison of in vitro Fertilization/Intracytoplasmic Sperm Injection Outcomes in Patients receiving Recombinant Human Luteinizing Hormone vs Human Menopausal Gonadotropin Supplementation

DB Usha Rajinikanthan, Thankam Varma

Citation Information : Rajinikanthan DU, Varma T. Comparison of in vitro Fertilization/Intracytoplasmic Sperm Injection Outcomes in Patients receiving Recombinant Human Luteinizing Hormone vs Human Menopausal Gonadotropin Supplementation. Int J Infertil Fetal Med 2016; 7 (3):77-81.

DOI: 10.5005/jp-journals-10016-1133

License: CC BY-NC 4.0

Published Online: 01-12-2016

Copyright Statement:  Copyright © 2016; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Objectives

To compare the outcome of recombinant human luteinizing hormone (rh-LH) and human menopausal gonadotropin (hMG) supplementation in women undergoing in vitro fertilization/ intracytoplasmic sperm injection (IVF/ICSI) with recombinant follicle stimulating hormone (FSH) in the long gonadotropinreleasing hormone (GnRH) agonist stimulation protocol.

Materials and methods

It was a retrospective analysis of the case records of 90 consecutive women who underwent nondonor IVF/ICSI cycle with long GnRH agonist. All women received recombinant FSH on day 2/3 of the programming cycle. When the level of LH was < 0.5 mIU/mL during any phase of stimulation, then addition of LH either as rh-LH or hMG is given along with recombinant FSH.

Results

The number of oocytes collected, the number of oocytes in metaphase II (MII), and fertilization rate were similar in both groups. In addition, the mean number of embryos produced per cycle and the mean number of frozen embryos per cycle were similar in both groups. The cost of gonadotropin is similar in both groups. The ongoing pregnancy rate at 12 weeks was 20.4% after rh-FSH + hMG and 29.2% after rh-FSH + rh-LH (p-value = 0.092).

Conclusion

Supplementing recombinant FSH with recombinant LH (rh-LH) when compared with hMG does not show statistically significant increase in pregnancy rates. However, this study was a pilot venture to introduce the rh-LH into our practice and further randomized study is required to substantiate its use in assistive reproductive technology.

How to cite this article

Usha Rajinikanthan DB, Balasubramanyam S, Varma T. Comparison of in vitro Fertilization/Intracytoplasmic Sperm Injection Outcomes in Patients receiving Recombinant Luteinizing Hormone vs Human Menopausal Gonadotropin Supplementation. Int J Infertil Fetal Med 2016; 7(3):77-81.


PDF Share
  1. A prospective, randomized comparison of ovulation induction using highly purified follicle-stimulation hormone alone and with recombinant human luteinizing hormone in in-vitro fertilization. Hum Reprod 1999 Sep;14(9):2230-2235.
  2. Understanding the role of LH: myths and facts. Reprod BioMed Online 2007 Oct;15(4):468-477.
  3. Comparison of the effectiveness of recombinant and urinary FSH preparations in the achievement of follicular selection in chronic anovulation. Reprod Biomed Online 2001;3:195-198.
  4. Recombinant human follicle stimulating hormone (rh-FSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP): results of a randomized comparative study in women undergoing assisted reproductive techniques. Hum Reprod 1997 Oct;12(10):2133-2139.
  5. Recombinant Luteinizing Hormone (rhLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database Syst Rev 2007 Apr 18;(2):CD005070.
  6. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil Steril 2004 Dec;82(6):1521-1526.
  7. Clinical outcomes of ovulation induction in WHO Group I anovulatory women using r-hFSH + r-h LH in a 2:1 ratio compared to hMG. Hum Reprod 2010;25:i285-i321.
  8. Differences in gene expression of granulosa cells from women undergoing controlled ovarian hyperstimulation with either recombinant follicle-stimulating hormone or highly purified human menopausal gonadotropin. Fertil Steril 2009 May;91(5):1820-1830.
  9. Recombinant human follicle – stimulating hormone produces more oocytes with a lower total dose per cycle in assisted reproductive technologies compared with highly purified human menopausal gonadotrophin: a meta-analysis. Reprod Biol Endocrinol 2010 Sep 16;8:112.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.